261 related articles for article (PubMed ID: 31415908)
1. GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials.
Smits MM; Ten Kulve JS; van Bloemendaal L; Tonneijck L; Muskiet MHA; Kramer MHH; Ijzerman RG; van Raalte DH
Nutrition; 2019; 67-68():110524. PubMed ID: 31415908
[TBL] [Abstract][Full Text] [Related]
2. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
3. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
Lorenz M; Lawson F; Owens D; Raccah D; Roy-Duval C; Lehmann A; Perfetti R; Blonde L
Cardiovasc Diabetol; 2017 Jan; 16(1):6. PubMed ID: 28086882
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
6. Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.
Kang YM; Cho YK; Lee J; Lee SE; Lee WJ; Park JY; Kim YJ; Jung CH; Nauck MA
Diabetes Metab J; 2019 Aug; 43(4):410-421. PubMed ID: 30604598
[TBL] [Abstract][Full Text] [Related]
7. Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis.
Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Ji L; Zhan S
Endocrine; 2015 Apr; 48(3):794-803. PubMed ID: 25115635
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of glucagon-like peptide-1 receptor agonists.
Sfairopoulos D; Liatis S; Tigas S; Liberopoulos E
Hormones (Athens); 2018 Sep; 17(3):333-350. PubMed ID: 29949126
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
Guyton J; Jeon M; Brooks A
Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.
Zhang YS; Weng WY; Xie BC; Meng Y; Hao YH; Liang YM; Zhou ZK
Osteoporos Int; 2018 Dec; 29(12):2639-2644. PubMed ID: 30083774
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.
van Bloemendaal L; IJzerman RG; Ten Kulve JS; Barkhof F; Konrad RJ; Drent ML; Veltman DJ; Diamant M
Diabetes; 2014 Dec; 63(12):4186-96. PubMed ID: 25071023
[TBL] [Abstract][Full Text] [Related]
12. Comparative study on anorexigenic effect of glucagon-like peptide-1 receptor agonists in rats.
Wen S; Nguyen T; Xiao WZ; Wang CX; Gong M; Jin JL; Zhou LG
Sheng Li Xue Bao; 2019 Aug; 71(4):514-526. PubMed ID: 31440748
[TBL] [Abstract][Full Text] [Related]
13. Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys.
Thomsen M; Holst JJ; Molander A; Linnet K; Ptito M; Fink-Jensen A
Psychopharmacology (Berl); 2019 Feb; 236(2):603-611. PubMed ID: 30382353
[TBL] [Abstract][Full Text] [Related]
14. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
Østergaard L; Frandsen CS; Madsbad S
Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications.
Heile M; Wyne K; Billings LK; Cannon A; Handelsman Y; Shannon M
J Manag Care Spec Pharm; 2018 Sep; 24(9-a Suppl):S42-S52. PubMed ID: 30156446
[TBL] [Abstract][Full Text] [Related]
16. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
[TBL] [Abstract][Full Text] [Related]
18. GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner.
Liu J; Yang K; Xiao W; Le Y; Lang S; Zhang J; Wei R; Yang J; Hong T
Peptides; 2018 Aug; 106():83-90. PubMed ID: 30003931
[TBL] [Abstract][Full Text] [Related]
19. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Quan X; Ji L; Zhan S
Diabetes Res Clin Pract; 2015 Oct; 110(1):26-37. PubMed ID: 26358202
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Cheng L; Hu Y; Li YY; Cao X; Bai N; Lu TT; Li GQ; Li N; Wang AN; Mao XM
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3168. PubMed ID: 30974033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
